CXCR4 and diffuse large B-cell lymphoma: More specifically, high CXCR4 membrane expression was recently associated with disease progression in a small cohort of primary testicular DLBCL patients [23], with poor survival in a cohort of 94 DLBCL patients treated with rituximab-containing regimens (92.5% R-CHOP) [24], and with a tendency towards worse outcome in a cohort of 70 R-CHOP-treated DLBCL patients of which only 8 were classified as CXCR4-negative [30].